BridgeBio Pharma (BBIO) said Monday acoramidis showed "statistically significant improvements" in clinical outcomes in both variant and wild-type transthyretin amyloid cardiomyopathy, or ATTR-CM, in a phase 3 trial.
The study compared acoramidis with placebo for time to all-cause mortality or first cardiovascular-related hospitalization in both variant and wild-type ATTR-CM, the company said.
Data showed that acoramidis increased serum transthyretin concentrations along with a 59.1% reduction in the risk of mortality or first hospitalization compared with placebo in patients with variant ATTR-CM, and 31.2% risk reduction in patients with wild-type ATTR-CM at month 30, according to the company.
Acoramidis also stabilized TTR levels in both patient groups, demonstrating over 90% stabilization, the company said.
Acoramidis is approved as Attruby in the US and as Beyonttra in the European Union and Japan.
Price: 34.62, Change: -0.49, Percent Change: -1.40
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。